CompletedPhase 2NCT05143190

Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)

Studying Dystrophic epidermolysis bullosa

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Phoenix Tissue Repair, Inc.
Principal Investigator
Dan Rudin, MD
Phoenix Tissue Repair
Intervention
PTR-01(drug)
Enrollment
2 enrolled
Eligibility
12 years · All sexes
Timeline
2021 – 2022

Study locations (2)

Collaborators

Phoenix Tissue Repair, a BridgeBio company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05143190 on ClinicalTrials.gov

Other trials for Dystrophic epidermolysis bullosa

Additional recruiting or active studies for the same condition.

See all trials for Dystrophic epidermolysis bullosa →

← Back to all trials